Sugi Predict

Sugi Predict / Compounds / SCHEMBL7213273

SCHEMBL7213273

SCHEMBL7213273

Cc1ccc(NC(O)=S)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.61
▸ RAB9A P51151 6/20 0.61
▸ HPGD P15428 1/20 0.61
▸ CYP1A2 P05177 2/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ CYP2C19 P33261 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ TDP1 Q9NUW8 2/20 0.54
▸ POLB P06746 2/20 0.52
▸ GAA P10253 2/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ CCR6 P51684 1/20 0.50
▸ GLA P06280 1/20 0.49
▸ CACNA1B Q00975 1/20 0.49
▸ APBA1 Q02410 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL11782099 0.91 NPC1 (0.53) NPC1RAB9AHPGDCYP1A2CYP3A4
Methane SCHEMBL8999429 0.89 NPC1 (0.52) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL11410456 0.82 CYP1A2 (0.59) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL1276739 0.82 KMT2A (0.79) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL863133 0.80 TAS2R38 (0.62) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL5451731 0.79 ALDH1A1 (0.74) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL7213269 0.78 TDP1 (0.58) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL9192272 0.78 CYP1A2 (0.55) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL4499052 0.78 CYP1A2 (0.55) NPC1RAB9AHPGDCYP1A2CYP3A4
SCHEMBL1278440 0.78 ALDH1A1 (0.61) NPC1RAB9AHPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12060334-B2 3-substituted phenazine derivatives as antimicrobial agents UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-08-13 — — US claimed
EP-3715346-B1 THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES DANA FARBER CANCER INST INC (US) 2024-01-03 — — EP claimed
EP-2970107-B1 PHOTOSWITCHABLE HDAC INHIBITORS MASSACHUSETTS GEN HOSPITAL (US) 2023-11-15 — — EP claimed
EP-3291676-B1 MITRAGYNINE ANALOGS AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-08-17 — — EP claimed
JP-8301841-A — — None — — JP disclosed
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 — — US disclosed
US-12637672-B2 Oligonucleotide compositions and methods thereof WAVE LIFE SCIENCES LTD. (SG) 2026-05-26 — — US disclosed
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 — — US disclosed
US-20260137789-A1 BRUSH PRODRUGS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-05-21 — — US disclosed
US-20260137806-A1 INTERCALATING SUGAR MOLECULES XALUD THERAPEUTICS, INC. (US) 2026-05-21 — — US disclosed
WO-2026107134-A1 USE OF SMALL MOLECULE GLUTAMINASE INHIBITORS FOR TREATING AGE-RELATED DISORDERS LEAL THERAPEUTICS, INC. (US) 2026-05-21 — — WO disclosed
WO-2026107431-A1 STEREOSELECTIVE SYNTHESIS OF L,2-CIS-2-AMINOGLYCOSIDES BRANDEIS UNIVERSITY (US) 2026-05-21 — — WO disclosed
CN-109136974-B C (sp) -containing2) Process for producing (E) -N bond compound 中国科学院上海有机化学研究所 2019-12-31 — — CN disclosed
CN-105792852-B Glucose-responsive insulin conjugates 默沙东公司 2019-12-10 — — CN disclosed
US-RE37979-E1 Pyrimidine derivatives and anti-viral agent containing the same as active ingredient thereof MITSUBISHI CHEMICAL CORPORATION 2003-02-04 — — US disclosed
EP-0829476-B1 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof MITSUBISHI CHEM CORP (JP) 2002-08-28 — — EP disclosed
EP-0829476-A2 6-Substituted acyclopyrimidine nucleoside derivatives and antiviral agent containing the same as active ingredient thereof Mitsubishi Chemical Corporation (JP) 1998-03-18 — — EP disclosed
JP-H08301841-A SQUALENE-EPOXYDASE ACTIVITY INHIBITOR GREEN CROSS CORP:THE 1996-11-19 — — JP disclosed
US-5461060-A Antiretroviral activity MITSUBISHI KASEI CORPORATION (JP) 1995-10-24 — — US disclosed
EP-0211806-B1 ADDITIVES FOR LUBRICATING COMPOSITIONS CIBA-GEIGY AG (CH) 1990-01-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137789-A1 BRUSH PRODRUGS AND USES THEREOF ABCB11, SLC10A2, CES2 NPC1 295/4885RAB9A 2684/4885HPGD 3004/4885
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof CDK1, CDK11A, CDK11B NPC1 1147/4885RAB9A 2872/4885HPGD 1906/4885
US-12637672-B2 Oligonucleotide compositions and methods thereof UPF1, SMN1; SMN2, RNGTT NPC1 3087/4885RAB9A 4114/4885HPGD 4878/4885
US-20260137806-A1 INTERCALATING SUGAR MOLECULES SLC2A1, SLC2A2, SLC2A4 NPC1 476/4885RAB9A 609/4885HPGD 3349/4885
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof MAP3K1, MAP3K3, MAPK1 NPC1 1455/4885RAB9A 1073/4885HPGD 1857/4885
US-12060334-B2 3-substituted phenazine derivatives as antimicrobial agents ROS1, NOX4, NOX5 NPC1 2759/4885RAB9A 2373/4885HPGD 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.